loading
Precedente Chiudi:
$54.62
Aprire:
$55
Volume 24 ore:
43,092
Relative Volume:
0.08
Capitalizzazione di mercato:
$3.10B
Reddito:
$32.87M
Utile/perdita netta:
$674.31M
Rapporto P/E:
-13.67
EPS:
-3.95
Flusso di cassa netto:
$-330.11M
1 W Prestazione:
-2.28%
1M Prestazione:
+18.56%
6M Prestazione:
+59.78%
1 anno Prestazione:
+147.53%
Intervallo 1D:
Value
$53.94
$55.29
Intervallo di 1 settimana:
Value
$52.09
$55.67
Portata 52W:
Value
$20.96
$62.58

Agios Pharmaceuticals Inc Stock (AGIO) Company Profile

Name
Nome
Agios Pharmaceuticals Inc
Name
Telefono
617-649-8600
Name
Indirizzo
88 SIDNEY STREET, CAMBRIDGE, MA
Name
Dipendente
386
Name
Cinguettio
@AgiosPharma
Name
Prossima data di guadagno
2024-10-31
Name
Ultimi documenti SEC
Name
AGIO's Discussions on Twitter

Confronta AGIO con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
AGIO 54.01 3.10B 32.87M 674.31M -330.11M -3.95
VRTX 447.58 115.74B 10.63B -479.80M -1.35B 13.33
REGN 741.92 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 589.39 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.84 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 103.41 24.49B 3.30B -501.07M 1.03B 11.54

Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-02-08 Iniziato Cantor Fitzgerald Overweight
2023-02-03 Iniziato Piper Sandler Overweight
2022-11-17 Aggiornamento Goldman Sell → Neutral
2022-07-27 Aggiornamento SVB Leerink Mkt Perform → Outperform
2021-12-03 Iniziato BofA Securities Buy
2021-07-30 Downgrade Goldman Neutral → Sell
2021-07-01 Iniziato Raymond James Mkt Perform
2021-06-10 Iniziato H.C. Wainwright Buy
2021-03-01 Downgrade JP Morgan Overweight → Neutral
2021-03-01 Aggiornamento SVB Leerink Mkt Perform → Outperform
2021-02-26 Downgrade SVB Leerink Outperform → Mkt Perform
2020-10-22 Aggiornamento Barclays Equal Weight → Overweight
2020-03-04 Iniziato Barclays Equal Weight
2019-11-26 Iniziato Cantor Fitzgerald Overweight
2019-09-23 Aggiornamento Guggenheim Neutral → Buy
2019-05-23 Ripresa Goldman Neutral
2019-02-15 Aggiornamento SVB Leerink Mkt Perform → Outperform
2018-09-25 Iniziato Leerink Partners Mkt Perform
2018-05-23 Iniziato Citigroup Buy
2018-04-11 Reiterato Credit Suisse Outperform
2018-02-15 Reiterato Needham Buy
2018-02-15 Reiterato SunTrust Buy
2017-09-15 Iniziato RBC Capital Mkts Outperform
2017-08-10 Reiterato Needham Buy
2017-08-08 Reiterato SunTrust Buy
2017-08-02 Aggiornamento Leerink Partners Mkt Perform → Outperform
2017-06-26 Downgrade Janney Buy → Neutral
2017-01-17 Aggiornamento Oppenheimer Perform → Outperform
2016-10-24 Iniziato Needham Buy
2016-06-13 Aggiornamento JP Morgan Neutral → Overweight
2016-05-18 Reiterato SunTrust Buy
Mostra tutto

Agios Pharmaceuticals Inc Borsa (AGIO) Ultime notizie

pulisher
05:06 AM

(AGIO) Pivots Trading Plans and Risk Controls - Stock Traders Daily

05:06 AM
pulisher
Nov 20, 2024

C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors - GlobeNewswire Inc.

Nov 20, 2024
pulisher
Nov 17, 2024

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Sees Significant Growth in Short Interest - MarketBeat

Nov 17, 2024
pulisher
Nov 16, 2024

Brokerages Set Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Price Target at $52.33 - MarketBeat

Nov 16, 2024
pulisher
Nov 14, 2024

ARMISTICE CAPITAL, LLC Expands Portfolio with Agios Pharmaceuticals Inc - GuruFocus.com

Nov 14, 2024
pulisher
Nov 12, 2024

Agios Pharmaceuticals director sells shares worth $1.12 million By Investing.com - Investing.com Canada

Nov 12, 2024
pulisher
Nov 12, 2024

Agios Pharmaceuticals chief legal officer sells $1.14 million in stock - Investing.com India

Nov 12, 2024
pulisher
Nov 12, 2024

Agios Pharmaceuticals chief legal officer sells $1.14 million in stock By Investing.com - Investing.com UK

Nov 12, 2024
pulisher
Nov 09, 2024

StockNews.com Upgrades Agios Pharmaceuticals (NASDAQ:AGIO) to Hold - MarketBeat

Nov 09, 2024
pulisher
Nov 08, 2024

Agios stock soars to 52-week high, reaching $53.28 By Investing.com - Investing.com Canada

Nov 08, 2024
pulisher
Nov 07, 2024

Agios stock soars to 52-week high, reaching $53.28 - Investing.com

Nov 07, 2024
pulisher
Nov 07, 2024

Agios Pharmaceuticals (NASDAQ:AGIO) Is Posting Healthy Earnings, But It Is Not All Good News - Yahoo Finance

Nov 07, 2024
pulisher
Nov 05, 2024

Agios Pharmaceuticals' SWOT analysis: promising pipeline, cash boost fuel stock outlook - Investing.com India

Nov 05, 2024
pulisher
Nov 05, 2024

Mirae Asset Global Investments Co. Ltd. Acquires 363 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World

Nov 05, 2024
pulisher
Nov 05, 2024

Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition - The Manila Times

Nov 05, 2024
pulisher
Nov 05, 2024

Agios to Unveil Critical Phase 3 Data for Blood Disorder Drugs at ASH 2024 | AGIO Stock News - StockTitan

Nov 05, 2024
pulisher
Nov 04, 2024

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Sold by Assenagon Asset Management S.A. - MarketBeat

Nov 04, 2024
pulisher
Nov 03, 2024

Agios Pharmaceuticals (NASDAQ:AGIO) Rating Lowered to “Sell” at StockNews.com - Defense World

Nov 03, 2024
pulisher
Nov 02, 2024

Agios Pharmaceuticals (NASDAQ:AGIO) Downgraded to "Sell" Rating by StockNews.com - MarketBeat

Nov 02, 2024
pulisher
Nov 01, 2024

Deep Dive Into Alnylam Pharmaceuticals Stock: Analyst Perspectives (6 Ratings) - Benzinga

Nov 01, 2024
pulisher
Nov 01, 2024

Agios Pharmaceuticals (NASDAQ:AGIO) Given "Outperform" Rating at Royal Bank of Canada - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

AGIO's Q3 Earnings Miss Mark, Revenues In Line, Stock Down - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

Agios Pharmaceuticals (NASDAQ:AGIO) Given New $53.00 Price Target at Scotiabank - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

Agios shares hold Strong Buy rating, $51 target from Raymond James - Investing.com Australia

Nov 01, 2024
pulisher
Nov 01, 2024

Earnings call: Agios Pharmaceuticals reports Q3 2024 financials, plans launches - Investing.com Australia

Nov 01, 2024
pulisher
Nov 01, 2024

Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

Agios Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 01, 2024
pulisher
Nov 01, 2024

Agios Pharmaceuticals Inc (AGIO) Q3 2024 Earnings Call Highlights: Strong Cash Position and ... - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

Agios Pharmaceuticals Inc (AGIO) Q3 2024 Earnings Call Highlights: Strong Cash Position and Strategic Advancements - GuruFocus.com

Nov 01, 2024
pulisher
Nov 01, 2024

Agios Pharmaceuticals: Q3 Earnings Snapshot - The Advocate

Nov 01, 2024
pulisher
Nov 01, 2024

Agios Pharmaceuticals Reports Robust Q3 2024 Results - TipRanks

Nov 01, 2024
pulisher
Oct 31, 2024

Agios Pharmaceuticals (AGIO) Misses Q3 Earnings and Revenue Estimates - MSN

Oct 31, 2024
pulisher
Oct 31, 2024

Agios Pharmaceuticals Inc (AGIO) Q3 2024 Earnings: EPS Surpasses Estimates, Revenue at $9.0 Million - GuruFocus.com

Oct 31, 2024
pulisher
Oct 31, 2024

Agios Reports Business Highlights and Third Quarter 2024 Financial Results - The Manila Times

Oct 31, 2024
pulisher
Oct 30, 2024

Earnings Preview: Agios Pharmaceuticals - Benzinga

Oct 30, 2024
pulisher
Oct 30, 2024

Leerink Partnrs Issues Optimistic Estimate for AGIO Earnings - MarketBeat

Oct 30, 2024
pulisher
Oct 25, 2024

Analysts Are Optimistic We'll See A Profit From Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Simply Wall St

Oct 25, 2024
pulisher
Oct 25, 2024

Equities Analysts Set Expectations for AGIO Q3 Earnings - MarketBeat

Oct 25, 2024
pulisher
Oct 24, 2024

Agios Pharmaceuticals' SWOT analysis: stock outlook amid SCD market shifts By Investing.com - Investing.com Australia

Oct 24, 2024
pulisher
Oct 24, 2024

Agios Pharmaceuticals (AGIO) Set to Announce Quarterly Earnings on Thursday - MarketBeat

Oct 24, 2024
pulisher
Oct 24, 2024

Agios Pharmaceuticals' SWOT analysis: stock outlook amid SCD market shifts - Investing.com India

Oct 24, 2024
pulisher
Oct 24, 2024

Servier vorasidenib PDUFA near, Agios wins in thalassemia - BioWorld Online

Oct 24, 2024
pulisher
Oct 24, 2024

Agios completes enrollment for sickle cell disease trial By Investing.com - Investing.com Canada

Oct 24, 2024
pulisher
Oct 23, 2024

Agios completes enrollment for sickle cell disease trial - Investing.com

Oct 23, 2024
pulisher
Oct 23, 2024

Agios Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease - The Manila Times

Oct 23, 2024
pulisher
Oct 22, 2024

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Oct 22, 2024

Agios Pharmaceuticals Inc Azioni (AGIO) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Agios Pharmaceuticals Inc Azioni (AGIO) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Ballal Rahul D.
Director
Nov 07 '24
Option Exercise
25.99
10,000
259,900
17,992
Ballal Rahul D.
Director
Nov 08 '24
Option Exercise
25.99
10,000
259,900
17,992
Ballal Rahul D.
Director
Nov 08 '24
Sale
58.19
10,000
581,911
7,992
Ballal Rahul D.
Director
Nov 07 '24
Sale
53.52
10,000
535,236
7,992
Burns James William
Chief Legal Officer
Nov 07 '24
Sale
52.21
21,752
1,135,775
15,700
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Capitalizzazione:     |  Volume (24 ore):